MX2022001712A - Conjugados y usos de los mismos. - Google Patents

Conjugados y usos de los mismos.

Info

Publication number
MX2022001712A
MX2022001712A MX2022001712A MX2022001712A MX2022001712A MX 2022001712 A MX2022001712 A MX 2022001712A MX 2022001712 A MX2022001712 A MX 2022001712A MX 2022001712 A MX2022001712 A MX 2022001712A MX 2022001712 A MX2022001712 A MX 2022001712A
Authority
MX
Mexico
Prior art keywords
treatment
conjugate
present
therapeutic molecule
peptide carrier
Prior art date
Application number
MX2022001712A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Wood
Michael Gait
Miguel Varela
Ashling Holland
Richard Raz
Denis Furling
Arnaud Klein
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MX2022001712A publication Critical patent/MX2022001712A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022001712A 2019-08-09 2020-08-07 Conjugados y usos de los mismos. MX2022001712A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1911403.2A GB201911403D0 (en) 2019-08-09 2019-08-09 Conjugate and uses thereof
PCT/GB2020/051891 WO2021028666A1 (en) 2019-08-09 2020-08-07 Conjugate and uses thereof

Publications (1)

Publication Number Publication Date
MX2022001712A true MX2022001712A (es) 2022-05-13

Family

ID=67990936

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001712A MX2022001712A (es) 2019-08-09 2020-08-07 Conjugados y usos de los mismos.

Country Status (13)

Country Link
US (1) US20220275372A1 (cg-RX-API-DMAC7.html)
EP (1) EP4010030A1 (cg-RX-API-DMAC7.html)
JP (1) JP7678654B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220079524A (cg-RX-API-DMAC7.html)
CN (2) CN114615998B (cg-RX-API-DMAC7.html)
AU (1) AU2020327659A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022002309A2 (cg-RX-API-DMAC7.html)
CA (1) CA3149700A1 (cg-RX-API-DMAC7.html)
GB (1) GB201911403D0 (cg-RX-API-DMAC7.html)
IL (1) IL290424A (cg-RX-API-DMAC7.html)
MX (1) MX2022001712A (cg-RX-API-DMAC7.html)
SA (1) SA522431627B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021028666A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018150196A1 (en) 2017-02-17 2018-08-23 Oxford University Innovation Limited Cell penetrating peptides modified by glycosylation
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
AU2019394177A1 (en) * 2018-12-07 2021-06-10 Oxford University Innovation Limited Linkers
CA3211038A1 (en) 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
US20240189434A1 (en) * 2021-03-12 2024-06-13 Pepgen Inc. Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates
IL321025A (en) * 2022-11-21 2025-07-01 Pepgen Inc Cell-penetrating peptides, conjugates thereof, and methods of their use
EP4759826A1 (en) * 2023-08-07 2026-06-17 Toagosei Co., Ltd. Peptide fragment and use thereof
WO2025033255A1 (ja) * 2023-08-07 2025-02-13 東亞合成株式会社 ペプチドフラグメント及びその利用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6047270B2 (ja) * 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー.フェー. Dnaリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
CA2691673A1 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2009147368A1 (en) * 2008-06-04 2009-12-10 Medical Research Council Peptides
US20110269665A1 (en) * 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2013030569A2 (en) * 2011-08-30 2013-03-07 Michael John Gait Peptides
US10111962B2 (en) 2012-09-25 2018-10-30 Genzyme Corporation Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения

Also Published As

Publication number Publication date
JP2022543320A (ja) 2022-10-11
CA3149700A1 (en) 2021-02-18
JP7678654B2 (ja) 2025-05-16
CN114615998A (zh) 2022-06-10
BR112022002309A2 (pt) 2022-04-26
GB201911403D0 (en) 2019-09-25
CN120837670A (zh) 2025-10-28
US20220275372A1 (en) 2022-09-01
EP4010030A1 (en) 2022-06-15
KR20220079524A (ko) 2022-06-13
CN114615998B (zh) 2025-05-23
SA522431627B1 (ar) 2024-05-19
WO2021028666A1 (en) 2021-02-18
IL290424A (en) 2022-04-01
AU2020327659A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
SA522431627B1 (ar) متقارن واستخداماته
MX2026000051A (es) Peptidos penetrantes celulares
PH12022500032A1 (en) Conjugates of a cell-binding molecule with camptothecin analogs
MX2024012513A (es) Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica
TW200738877A (en) Immunostimulatory oligoribonucleotides
NZ790263A (en) Exon skipping compositions for treating muscular dystrophy
CR20190481A (es) Composiciones de anticuerpo optimizados para el tratamiento de trastornos oculares
PH12011502391A1 (en) A㟠immunogenic peptide carrier conjugates and methods of producing same
WO2019136180A3 (en) Heteroduplex nucleic acid molecules and uses thereof
MY146566A (en) Immunogenic peptide carrier conjugates and methods of producing same
EP3949969A3 (en) Benzazepine compounds, conjugates, and uses thereof
ZA201903062B (en) Amanitin antibody conjugates
MX2020012679A (es) Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
TW200621801A (en) Antibody molecules having specificity for human IL-17
MX2024005831A (es) Conjugado de anticuerpo biespecifico-farmaco de camptotecina y uso farmaceutico del mismo.
EA202192137A1 (ru) Конъюгат аматоксинового аналога с разветвленными линкерами
TW200531689A (en) Therapeutic agents
MX2021006726A (es) Enlazadores.
WO2014057436A3 (en) Anticancer conjugate
MX2021005346A (es) Constructos de suministro para transcitosis y metodos relacionados.
PH12020500417A1 (en) Anti-efgr antibody drug conjugates (adc) and uses thereof
MX2021001546A (es) Péptidos penetrantes celulares.
PE20141706A1 (es) Anticuerpos de union a trombina y usos del mismo
MX2022014538A (es) Moleculas de union para el tratamiento de cancer.
ATE451919T1 (de) Hydrochinon- ansamycinen in der behandlung von gastrointestinalen stromatumoren